Hunt Technology Ventures
VC Fund
Dallas, United States
Hunt Technology Ventures is a VC fund in Dallas focused on Software and Logistics. Hunt Technology Ventures operates as a private technology investors.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Hunt Technology Ventures invests in
SoftwareLogisticsTransportationSaaSRetail
Stages Hunt Technology Ventures invests in
SeedSeries AFunding RoundSeries BSeries C
Countries Hunt Technology Ventures invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Software 4 (19%)
- Logistics 3 (14%)
- Transportation 3 (14%)
- SaaS 2 (10%)
- Retail 2 (10%)
Stage
- Seed 7 (33%)
- Series A 7 (33%)
- Funding Round 3 (14%)
- Series B 1 (5%)
- Series C 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Hunt
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Digital Insight Games
|
Digital Insight Games develops a gaming studio intended to build AAA blockchain RPGs. It was founded in 2019. | $7.5M / Mar 15, 2022 | |
|
Digital Insight Games
|
Digital Insight Games develops a gaming studio intended to build AAA blockchain RPGs. It was founded in 2019. | $7.5M / Series A / Mar 15, 2022 | |
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M / Series B / Oct 21, 2021 | |
eGroup
|
eGroup delivers technology solutions for serious competitors. Founded in 1999, it is a Microsoft partner with seven Microsoft Gold competencies including Gold Cloud Platform (Microsoft Azure) and Gold Cloud Productivity (Microsoft 365), and is an Elite Microsoft Security and Management partner with an Advanced Specialization in Azure VirtualDesktops. | Private Equity / Oct 13, 2021 | |
ClearRoad
|
ClearRoad is reassessing the value of public space and building the funding infrastructure for the future of mobility. The ClearRoad IoT platform facilitates the monetization of roads by government agencies across North America through road usage pricing. It flexibly operates under any programmatic and regulatory designs, across a range ofexisting and planned vehicle usage identification technologies. The company has already established itself in this nascent space, with existing per-mile programs in Oregon and Washington State, and partnerships with established leaders in the tolling and telematics industries. If we’re going to get the congestion pricing we need to reduce traffic in our cities, government agencies will need help to automate toll road pricing for any section of road without the need for traditional proprietary hardware infrastructure. | $2.4M / Seed / Jul 27, 2021 | |
The Arena Group
|
The Arena Group provides dynamic, digital destinations that delight consumers with stories and news about the things they love – their favorite sports teams, the inside scoop on personal finance, and the latest on lifestyle essentials. We are building out a dynamic media ecosystem that brings together consumers, publishers and advertisers in aproven strategy that brings sustainable performance gains in traffic, engagement, and monetization by harnessing the authority of sought-after brands and the editorial prowess of our leading writers and editors. In this way we leverage a single platform to scale utilizing best in class capabilities in direct sales and programmatic advertising, data, SEO, social, and operations. | $20M / Post-IPO Equity / Jun 07, 2021 | |
Silverback Therapeutics
|
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible.Silverback Therapeutics is building aplatform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease. | $85M / Series C / Sep 23, 2020 | |
Artimus Robotics
|
Artimus Robotics works towards enabling a new generation of robots and machines that increase productivity and improve quality of life. | Seed / Aug 12, 2020 | |
|
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M / Series A / Mar 26, 2020 | |
Totum Labs
|
Totum enables the worldwide tracking and monitoring of billions of assets using their constellation of Low Earth Orbit (LEO) nanosatellites. | $9M / Seed / Nov 15, 2019 | |
| See all 21 investments → | |||
Co-Investors
GrowthX
4 deals together
Heroic Ventures
4 deals together
Covera Ventures
3 deals together
OrbiMed
3 deals together
1517 Fund
2 deals together
Colt Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Marketplace Investors
40,654 investors
Transportation Investors
27,893 investors
Retail Investors
12,193 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Marketplace VC Funds
26,677 investors
Transportation VC Funds
21,585 investors
FAQ
What does Hunt Technology Ventures invest in?
Hunt Technology Ventures invests primarily in Software, Logistics and Transportation startups, most often at Seed and Series A stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hunt Technology Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hunt Technology Ventures?
The team at Hunt Technology Ventures includes David Hunt (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
